When should mood stabilizers be withdrawn due to lack of efficacy? Some methodological considerations

European Psychiatry

Volumn 26, Issue 3, 2011, Pages 183-186

  Murru, A ^a   Colom, F ^a   Nivoli, A ^a   Pacchiarotti, I ^a   Valenti, M ^a   Vieta, E ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Bipolar disorder; Lack of efficacy; Maintenance treatment; Mood stabilizer

Indexed keywords

LITHIUM; MOOD STABILIZER; OXCARBAZEPINE; QUETIAPINE;

BIPOLAR DISORDER; CLINICAL PRACTICE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; SHORT SURVEY; TREATMENT RESPONSE;

ANTIMANIC AGENTS; BIPOLAR DISORDER; HUMANS; TREATMENT FAILURE; WITHHOLDING TREATMENT;

EID: 79953306221     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2010.09.012     Document Type: Short Survey

References (22)

1. Baldessarini R., Henk H., Sklar A., Chang J., Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 2008, 59(10):1175-1183.
2. Baldessarini R.J., Tondo L., Davis P., Pompili M., Goodwin F.K., Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006, 8(5 Pt 2):625-639.
3. Corbella B., Vieta E. Molecular targets of lithium action. Acta Neuropsychiatrica 2003, 15:316-340.
4. Endicott J., Rajagopalan K., Minkwitz M., Mcfadden W. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 2007, 22(1):29-37. BOLDER Study Group.
5. Goodwin F.K., Jamison K. Manic-Depressive Illness. Bipolar disorders and recurrent depression 2007, Oxford Press. 2nd Ed.
6. Goodwin G. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009, 23(4):346-388. Consensus Group of the British Association for Psychopharmacology.
7. Goodwin G.M., Anderson I., Arango C., Bowden C.L., Henry C., Mitchell P.B., et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol 2008, 18(7):535-549.
8. Gould T.D., Quiroz J.A., Singh J., Zarate C.A., Manji H.K. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004, 9:734-755.
9. Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Moller H.J., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. World J Biol Psychiatry 2009, 10(2):85-116.
10. Kasper S., Calabrese J.R., Johnson G., Tajima O., Vieta E., Viguera A.C., et al. International Consensus Group on the Evidence-based Pharmacological Treatment of Bipolar I and II Depression. J Clin Psychiatry 2008, 69:1632-1646.
11. Leverich G.S., Post R.M. Life charting the course of bipolar disorder. Curr Rev Mood Anxiety Disord 1996, 1:48-61.
12. Mistler L.A., Mellman T.A., Drake R.E. A pilot study testing a medication algorithm to reduce polypharmacy. Qual Saf Health Care 2009, 18(1):55-58.
13. NICE clinical guidelines 38. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence. 2009 update.
14. Post R.M., Denicoff K.D., Leverich G.S., Altshuler L.L., Frye M.A., Suppes T.M., et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003, 64:680-690.
15. Rapoport S.I., Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?. Arch Gen Psychiatry 2002, 59:592-596.
16. Schumock G.T., Walton S.M., Park H.Y., Nutescu E.A., Blackburn J.C., Finley J.M., et al. Factors that influence prescribing decisions. Ann Pharmacother 2004, 38:557-562.
17. Serretti A., Artioli P. Predicting response to lithium in mood disorders: role of genetic polymorphisms. Am J Pharmacogenomics. 2003, 3(1):17-30.
18. Suppes T., Dennehy E.B., Hirschfeld R.M., Altshuler L.L., Bowden C.L., Calabrese J.R., et al. Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005, 66(7):870-886.
19. Swann A.C., Bowden C.L., Calabrese J.R., Dilsaver S.C., Morris D.D. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999, 156(8):1264-1266.
20. Tohen M., Frank E., Bowden C.L., Colom F., Ghaemi S.N., Yatham L.N., et al. The International Society of Bipolar Disorders (ISBD) Task Force on the Nomenclature of Course and Outcome in Bipolar Disorders. Bipolar Disord 2009, 11(5):453-473.
21. Vieta E., Cruz N., García-Campayo J., de Arce R., Manuel Crespo J., Vallès V., et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008, 11(4):445-452.
22. Yatham L.N., Kennedy S.H., Schaffer A., Parikh S.V., Beaulieu S., O'Donovan C., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009, 11(3):225-255.